Source: https://patents.google.com/patent/US8096422B2/en
Timestamp: 2019-04-19 05:24:11+00:00

Document:
This application is a continuation of U.S. patent application Ser. No. 11/342,749 filed on Jan. 30, 2006, now U.S. Pat. No. 7,824,559; which application claims the benefit under 35 USC 120 of the filing dates of U.S. Provisional Application No. 60/651,050, filed on Feb. 7, 2005, U.S. Provisional Application No. 60/654,718, filed on Feb. 17, 2005, and U.S. Provisional Application No. 60/723,312, filed on Oct. 4, 2005. The entire disclosures of the above applications are incorporated herein by reference.
Platelet rich plasma is a concentrated platelet product that can be produced from whole blood through commercially available systems, resulting in varying levels of platelet concentration. Platelets play a crucial role in the signaling cascade of normal wound healing. Activated platelets release the contents of their α-granules resulting in a deposition of powerful growth factors such as platelet derived growth factor (PDGF), transforming growth factor β-(TGF-β), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF). PRP has been used in many different clinical applications, demonstrating the effectiveness and importance of the product for a variety of medical procedures. For example, percutaneous application of PRP to patients with severe lateral epicondylitis, or tennis elbow, resulted in improved elbow function and reduced pain. Early maturation of bony fusion was observed when platelet concentrate was used during lumbar spinal fusions. Chronic diabetic foot ulcers treated with PRP achieved increased healing rates compared to the control group receiving standard care. Studies by Bhanot el at show decreased formation of hematoma and seroma, decreased postoperative swelling, and improved healing time for plastic surgeries that included PRP in the treatment. Further, during dental surgeries, the use of PRP has improved bone regeneration around implants.
If it is desirable to tolerate inaccuracy of introduced blood volume, the device can incorporate an overflow chamber as described in provisional patent application Ser. No. 60/654,718 filed Feb. 17, 2005 and concurrently filed application Ser. No. 11/342,761, now U.S. Pat. No. 7,708,152, issued on May 4, 2010, the contents of which are hereby incorporated by reference.
wherein the separation chamber is balanced for substantially vibration-free rotation about the axis.
a valve assembly positioned within the separation chamber to selectively allow a material to move into the PRP concentration assembly.
a PRP concentration sump defined at a center of the sloped floor.
4. The separator-concentrator of claim 3, wherein the stationary outlet tube extends to the PRP concentration sump and operable to allow withdrawal of a PRP concentrate from the PRP concentration sump through the stationary outlet tube.
5. The separator-concentrator of claim 3, wherein the at least one opening includes a plurality of openings defined by upright screen supports and the screen includes a cylindrical screen supported in the plurality of openings by the upright screen supports.
wherein the bead rake has distal ends that are spaced a distance from the concentration chamber wall.
wherein the rake longitudinal body has weakened fracture points near to the stationary tube, whereby the rake longitudinal body fractures when exposed to excessive strain due to contact with desiccated beads that have swelled.
wherein the combined separator-concentrator assembly is operable to be rotated about the outlet tube within the housing.
9. The separator-concentrator of claim 8, wherein the motor assembly comprises a motor control system for timed rotations of the drive coupling during an acceleration period of time, a rapid centrifugal erythrocyte separation period of time, a deceleration period of time, a slow stir concentrating period of time, an acceleration period of time, and a rapid centrifugal PRP concentrate separation period of time.
wherein the housing is operable to selectively engage the motor housing, wherein the housing is fixed relative to the motor housing during the engagement.
wherein a seal is formed in the closed position by cooperation of the valve face and the valve seat and the seal is disengaged in the opened position by movement of the valve face away from the valve seat.
a plurality of valve operator arms, each valve operator arm having an inflexible portion with a weighted distal end and a flexible proximal portion, each flexible proximal portion secured to the valve face member to move the valve face member thereby moving the valve face to the open position when the plurality of valve operator arms move away from the axis under centrifugal force during a selected rotation of the separator-concentrator assembly around the axis and to bias each of the plurality of valve operator arms towards the axis.
wherein the flexible proximal portions are positioned between at least two of the plurality of abutment plates and at least one of the plurality of the abutment plates contacts at least one of the plurality of valve operator arms to restrain the proximal portion against rotation around the axis when the valve operator arm is positioned near the axis.
14. The separator-concentrator of claim 13, wherein at least one of the plurality of abutment plates has a top edge to support at least one of the plurality of valve operator arms after the valve has moved to the open position thus preventing return movement of the valve operator arm towards the axis and to thereby prevent the valve face member from moving to the closed position.
wherein the combined separator-concentrator assembly is operable to be rotated about the outlet tube.
a concentrator material positioned within the PRP concentration chamber.
a rake including a body fixed to the stationary outlet tube and tines extending from the body to engage the concentrator material when the PRP concentration assembly spins around the axis.
the housing operable to selectively engage the motor housing, wherein the housing is fixed relative to the motor housing during the engagement.
wherein the tines are operable to engage the concentrator material when the PRP concentration assembly spins around the axis.
a valve assembly positioned substantially within the PRP separation assembly to selectively open to allow a material to move into the PRP concentration chamber.
Ann Thorac Surg, vol. 53, pp. 530-531, 1992, Mehmet C. Oz, M.D., et al., "Autologous Fibrin Glue From Intraoperatively Collected Platelet-Rich Plasma".
Collier, B.S. et al., "The pH Dependence of Quantitative Ristocetin-induced Platelet Aggregation: Theoretical and Practical Implications-A New Device for Maintenance of Platelet-Rich Plasma pH", Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, Md. 20014, Blood, vol. 47, No. 5 (May), 1976.
Collier, B.S. et al., "The pH Dependence of Quantitative Ristocetin-induced Platelet Aggregation: Theoretical and Practical Implications—A New Device for Maintenance of Platelet-Rich Plasma pH", Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, Md. 20014, Blood, vol. 47, No. 5 (May), 1976.
DelRossi, A. J., A. C. Cernaianu, R. A.Vertrees, C. J. Wacker, S. J. Fuller, J. Cilley Jr., and W. A. Baldino. "Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass." J Thorac Cardiovasc Surg 100 (2 1990): 281-6.
Gibble, J. W. and P. M. Ness. "Fibrin glue: the perfect operative sealant?" Transfusion 30 (8 1990): 741-7.
GPS® System, "Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques," Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 3 pages, http://www.cellfactortech.com/global-products.cfm, printed Sep. 16, 2005.
GPS® System, "Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques," Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 3 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
Harris, E.L.V. Concentration of the Extract. In. Protein Purification Methods: A Practical Approach Harris, E.L.V.; Angel, S.; Editors. (1989) Publisher: (IRL Press, Oxford, UK), pp. 67-69.
Hartman, A. R., D. K. Galanakis, M. P. Honig, F. C. Seifert, and C. E. Anagnostopoulos. "Autologous whole plasma fibrin gel. Intraoperative procurement." Arch Surg 127 (3 1992): 357-9.
Hennis, H. L., W. C. Stewart, and E. K. Jeter. "Infectious disease risks of fibrin glue [letter]." Ophthalmic Surg 23 (9 1992): 640.
International Preliminary Examination Report and Written Opinion issued Aug. 31, 2010 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008 of which U.S. Appl. No. 12/395,085, filed Feb. 27, 2009 claims benefit.
Kjaergard, H. K,, U. S. Weis-Fogh, H. Sorensen, J. Thiis, and I. Rygg. "A simple method of preparation o£ autologous fibrin glue by means of ethanol." Surg Gynecol Obstet 175 (1 1992): 72-3.
Kjaergard, H. K., Fogh Us Weis, and J. J. Thiis. "Preparation of autologous fibrin glue from pericardial blood." Ann Thorac Sur 55 (2 1993): 543-4.
Lerner, R. and N. S. Binur. "Current status of surgical adhesives." J Surg Res 48 (2 1990): 165-81.
Moretz, W., Jr., J Shea Jr., J. R. Emmett, and J Shea. "A simple autologous fibrinogen glue for otologic surgery." Otolaryngol Head Neck Surg 95 (1 1986): 122-4.
Nathan, Suresh,, et al., "Cell-Based Therapy in the Repair of Osteochondral Defects: A Novel Use for Adipose Tissue," Tissue Engineering, vol. 9, No. 4 (2003) pp. 733-744 Mary Ann Liebert, Inc.
Office Action mailed Sep. 14, 2010 for Japanese Application No. 2007554191, filed Aug. 7, 2007 has been provided including a partial translation thereof. Japanese Application No. 2007554191 claims benefit of PCT/US2006/003597, filed Jan. 30, 2006; claiming priority from U.S. Appl. No. 60/651,050, filed Feb. 7, 2005; U.S. Appl. No. 60/654,718, filed Feb. 17, 2005; and U.S. Appl. No. 60/723,312, filed Oct. 4, 2005 of which U.S. Appl. No. 11/831,605 filed Jul. 31, 2007 and U.S. Appl. No. 12/772,497, filed May 3, 2010 claim benefit.
Office Action mailed Sep. 14, 2010 for Japanese Application No. 2007-554193, filed Aug. 23, 2007 has been provided including a partial translation thereof. Japanese Application No. 2007-554193 claims benefit of PCT/US2006/003599, filed Jan. 30, 2006; claiming priority from U.S. Appl. No. 60/651,050, filed Feb. 7, 2005; U.S. Appl. No. 60/654,718, filed Feb. 17, 2005; and U.S. Appl. No. 60/723,312, filed Oct. 4, 2005 of which U.S. Appl. No. 11/831,605, filed Jul. 31, 2007 and U.S. Appl. No. 12/772,497, filed May 3, 2010 claim benefit.
Sanal, M. "Does fibrin glue cause foreign body reactions? [letter]." Eur J Pediatr Surg 3 (3 1993): 190 (1 page).
Sanal, M., H. Dogruyol, A. Gurpinar, and O. Yerci. "Does fibrin glue cause foreign body reactions?" Eu r J Pediatr Surg 2 (5 1992): 285-6.
Vox Sanquinis, vol. 68: 82-89, Feb. 1995, Boomgaard Et. al.
Weis-Fogh, U. S. "Fibrinogen prepared from small blood samples for autologous use in a tissue adhesive system." Eur Surg Res 20 (5-6 1988): 381-9.

References: Application No. 60
 Application No. 60
 Application No. 60
 Application No. 2007554191
 Application No. 2007554191
 Application No. 2007
 Application No. 2007